<p>随着全球市场继续应对货币政策变化和经济数据的影响，亚洲市场表现出韧性，科技和制造等行业活动显著。尽管历史上有负面含义，便士股票仍然被视为发现新兴公司的一个重要投资领域。这些较小或较新的公司在强大的财务健康支持下，可以提供增长机会，为投资者带来显著回报的潜力。</p>
<h3>亚洲十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们亚洲便士股票筛选器的 976 只股票的完整列表。</p>
<p>以下是筛选器中一些选择的预览。</p>
<h2>Cosmos Group (SZSE:002133)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Cosmos Group Co., Ltd. 在中国的房地产开发行业运营，市值为 CN¥28.7 亿。</p>
<p><strong>运营：</strong> 公司的收入主要来自其房地产部门，达到 CN¥32.7 亿，以及其交易活动的 CN¥19 亿。</p>
<p><strong>市值：</strong> CN¥28.7B</p>
<p>Cosmos Group Co., Ltd. 在其财务结构上表现出韧性，短期资产为 CN¥62 亿，足以覆盖短期和长期负债。尽管公司未盈利，但在 2025 年上半年报告了净收入 CN¥9066 万，较去年亏损有显著改善。最近的高管变动和对公司章程的提议修订可能表明旨在加强治理和运营效率的战略转变。公司的分红提案反映了尽管收益未能完全覆盖，但仍努力为股东回报价值，突显了与其财务可持续性战略相关的潜在风险。</p>
<ul>
<li>在这里深入了解 Cosmos Group 的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>查看我们的历史业绩报告，以获取 Cosmos Group 的业绩记录的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002133 户债务与股本历史及分析截至 2025 年 9 月</p>
<h2>天津追日药业有限公司 (SZSE:300026)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 天津追日药业有限公司从事药品的研究、开发、生产和销售，业务覆盖中国及国际市场，市值为 CN¥117.8 亿。</p>
<p><strong>运营：</strong> 天津追日药业有限公司未报告具体的收入细分。</p>
<p><strong>市值：</strong> CN¥117.8B</p>
<p>天津追日药业有限公司展现出稳健的财务状况，短期资产为 CN¥60 亿，超过其短期和长期负债。公司的债务管理良好，由运营现金流覆盖，且现金超过总债务。尽管过去五年亏损增加，公司在 2025 年上半年报告了净收入 CN¥7863 万，较去年有所下降。预计其收益将显著增长，尽管当前的负股本回报和分红可持续性对寻求稳定的便士股票投资者构成挑战。</p>
<ul>
<li>在我们的财务健康报告中更详细地了解天津追日药业有限公司的潜力。</li>
<li>通过访问我们的收益增长报告评估天津追日药业有限公司的前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis"/></p>
<p>SZSE:300026 财务状况分析截至 2025 年 9 月</p>
<h2>永益健康 (SZSE:300247)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> 永益健康有限公司在中国从事桑拿产品的制造、出口和销售，市值为 CN¥37.1 亿。</p>
<p><strong>运营：</strong> 永益健康有限公司未报告具体的收入细分。</p>
<p><strong>市值：</strong> CN¥37.1B</p>
<p>永益健康有限公司展现出强大的财务基础，短期资产为 CN¥9.989 亿，超过其短期和长期负债，并且没有债务。公司表现出令人印象深刻的收益增长，过去一年增长 92%，净利润率提高至 8.3%。尽管董事会经验较少，平均任期为 2.8 年，但管理团队经验丰富。2025 年上半年的最新收益报告显示，收入为 CN¥4.3276 亿，反映出在中国桑拿产品市场的强劲运营表现，尽管治理修订仍在进行中。</p>
<ul>
<li>在这里深入了解永益健康的完整分析健康报告。</li>
<li>通过我们的公司历史业绩报告获取永益健康的过去趋势和表现的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis"/></p>
<p>深交所：300247 财务状况分析截至 2025 年 9 月</p>
<h2>利用优势</h2>
<ul>
<li>在这里浏览 976 只亚洲便士股票的完整清单。</li>
<li>考虑其他策略？探索 24 家在下一代技术革命中处于领先地位的量子计算公司，这些公司通过量子算法、超导量子比特和前沿研究塑造未来。</li>
</ul>
<p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>

健倍苗苗

利华控股集团

<p>这篇文章讨论了三只市值低于 20 亿美元的亚洲便士股票，强调了它们尽管历史上存在风险，但仍具有增长潜力。这些股票包括 Food Moments、健倍苗苗和利华控股集团，每个公司在各自的行业中都表现出韧性。文章强调了这些小型公司的财务健康的重要性，指出它们可以为投资者提供显著的回报。此外，文章还提供了关于其他公司如 Cosmos Group 和天津追日药业的财务状况的见解，展示了它们的运营表现和面临的挑战</p>

<p>As global markets continue to navigate the impacts of monetary policy shifts and economic data, Asian markets have shown resilience with notable activity in sectors like technology and manufacturing. Penny stocks, often seen as a gateway to discovering emerging companies, remain a compelling investment area despite their historical connotations. These smaller or newer companies can offer growth opportunities when backed by strong financial health, providing investors with the potential for significant returns.</p>
<div class="lb-trans"><p>随着全球市场继续应对货币政策变化和经济数据的影响，亚洲市场表现出韧性，科技和制造等行业活动显著。尽管历史上有负面含义，便士股票仍然被视为发现新兴公司的一个重要投资领域。这些较小或较新的公司在强大的财务健康支持下，可以提供增长机会，为投资者带来显著回报的潜力。</p>
</div><h3>Top 10 Penny Stocks In Asia</h3>
<div class="lb-trans"><h3>亚洲十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>Food Moments (SET:FM)</td>
<td>THB4.00</td>
<td>THB3.95B</td>
<td>✅ 4 ⚠️ 0 查看分析</td>
</tr>
<tr>
<td>JBM (Healthcare) (SEHK:2161)</td>
<td>HK$3.05</td>
<td>HK$2.48B</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Lever Style (SEHK:1346)</td>
<td>HK$1.61</td>
<td>HK$995.82M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>TK Group (Holdings) (SEHK:2283)</td>
<td>HK$2.49</td>
<td>HK$2.07B</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CNMC Goldmine Holdings (Catalist:5TP)</td>
<td>SGD0.97</td>
<td>SGD393.13M</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>T.A.C. Consumer (SET:TACC)</td>
<td>THB4.96</td>
<td>THB2.98B</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Yangzijiang Shipbuilding (Holdings) (SGX:BS6)</td>
<td>SGD3.18</td>
<td>SGD12.52B</td>
<td>✅ 5 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Ekarat Engineering (SET:AKR)</td>
<td>THB0.98</td>
<td>THB1.44B</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Livestock Improvement (NZSE:LIC)</td>
<td>NZ$0.95</td>
<td>NZ$135.23M</td>
<td>✅ 2 ⚠️ 5 查看分析</td>
</tr>
<tr>
<td>Lum Chang Holdings (SGX:L19)</td>
<td>SGD0.43</td>
<td>SGD161.09M</td>
<td>✅ 2 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 976 stocks from our Asian Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们亚洲便士股票筛选器的 976 只股票的完整列表。</p>
</div><p>Here's a peek at a few of the choices from the screener.</p>
<div class="lb-trans"><p>以下是筛选器中一些选择的预览。</p>
</div><h2>Cosmos Group (SZSE:002133)</h2>
<div class="lb-trans"><h2>Cosmos Group (SZSE:002133)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Cosmos Group Co., Ltd. operates in the real estate development sector in China with a market capitalization of CN¥2.87 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Cosmos Group Co., Ltd. 在中国的房地产开发行业运营，市值为 CN¥28.7 亿。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its real estate segment at CN¥3.27 billion and its trading activities at CN¥1.90 billion.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入主要来自其房地产部门，达到 CN¥32.7 亿，以及其交易活动的 CN¥19 亿。</p>
</div><p><strong>Market Cap:</strong> CN¥2.87B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥28.7B</p>
</div><p>Cosmos Group Co., Ltd. has shown resilience in its financial structure, with short-term assets of CN¥6.2 billion comfortably covering both short-term and long-term liabilities. Despite being unprofitable, the company reported a net income of CN¥90.66 million for the first half of 2025, a significant improvement from a loss last year. Recent executive changes and proposed amendments to company bylaws may signal strategic shifts aimed at strengthening governance and operational efficiency. The company's dividend proposal reflects an effort to return value to shareholders despite earnings not fully covering it, highlighting potential risks associated with its financial sustainability strategy.</p>
<div class="lb-trans"><p>Cosmos Group Co., Ltd. 在其财务结构上表现出韧性，短期资产为 CN¥62 亿，足以覆盖短期和长期负债。尽管公司未盈利，但在 2025 年上半年报告了净收入 CN¥9066 万，较去年亏损有显著改善。最近的高管变动和对公司章程的提议修订可能表明旨在加强治理和运营效率的战略转变。公司的分红提案反映了尽管收益未能完全覆盖，但仍努力为股东回报价值，突显了与其财务可持续性战略相关的潜在风险。</p>
</div><ul>
<li>Dive into the specifics of Cosmos Group here with our thorough balance sheet health report.</li>
<li>Review our historical performance report to gain insights into Cosmos Group's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 Cosmos Group 的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>查看我们的历史业绩报告，以获取 Cosmos Group 的业绩记录的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a8f7b22a-78a2-4ab2-af45-17f92f677dbe/chart/debt-equity-history-analysis"/></p>
<p>SZSE:002133 Debt to Equity History and Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:002133 户债务与股本历史及分析截至 2025 年 9 月</p>
</div><h2>Tianjin Chase Sun PharmaceuticalLtd (SZSE:300026)</h2>
<div class="lb-trans"><h2>天津追日药业有限公司 (SZSE:300026)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.78 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 天津追日药业有限公司从事药品的研究、开发、生产和销售，业务覆盖中国及国际市场，市值为 CN¥117.8 亿。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd.</p>
<div class="lb-trans"><p><strong>运营：</strong> 天津追日药业有限公司未报告具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> CN¥11.78B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥117.8B</p>
</div><p>Tianjin Chase Sun Pharmaceutical Co., Ltd. demonstrates a solid financial position with short-term assets of CN¥6 billion exceeding both its short and long-term liabilities. The company's debt is well-managed, covered by operating cash flow, and it has more cash than total debt. Despite being unprofitable with increased losses over the past five years, the company reported net income of CN¥78.63 million for the first half of 2025, down from last year. Its earnings are forecast to grow significantly annually, though current negative return on equity and dividend sustainability pose challenges for investors seeking stability in penny stocks.</p>
<div class="lb-trans"><p>天津追日药业有限公司展现出稳健的财务状况，短期资产为 CN¥60 亿，超过其短期和长期负债。公司的债务管理良好，由运营现金流覆盖，且现金超过总债务。尽管过去五年亏损增加，公司在 2025 年上半年报告了净收入 CN¥7863 万，较去年有所下降。预计其收益将显著增长，尽管当前的负股本回报和分红可持续性对寻求稳定的便士股票投资者构成挑战。</p>
</div><ul>
<li>Take a closer look at Tianjin Chase Sun PharmaceuticalLtd's potential here in our financial health report.</li>
<li>Evaluate Tianjin Chase Sun PharmaceuticalLtd's prospects by accessing our earnings growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我们的财务健康报告中更详细地了解天津追日药业有限公司的潜力。</li>
<li>通过访问我们的收益增长报告评估天津追日药业有限公司的前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/56aef653-29e7-46d0-8533-ca47e06dfb33/chart/financial-position-analysis"/></p>
<p>SZSE:300026 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>SZSE:300026 财务状况分析截至 2025 年 9 月</p>
</div><h2>Youngy Health (SZSE:300247)</h2>
<div class="lb-trans"><h2>永益健康 (SZSE:300247)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Youngy Health Co., Ltd. is involved in the manufacture, export, and sale of sauna products in China with a market cap of CN¥3.71 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 永益健康有限公司在中国从事桑拿产品的制造、出口和销售，市值为 CN¥37.1 亿。</p>
</div><p><strong>Operations:</strong> Youngy Health Co., Ltd. does not report specific revenue segments.</p>
<div class="lb-trans"><p><strong>运营：</strong> 永益健康有限公司未报告具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> CN¥3.71B</p>
<div class="lb-trans"><p><strong>市值：</strong> CN¥37.1B</p>
</div><p>Youngy Health Co., Ltd. showcases a robust financial foundation, with short-term assets of CN¥998.9 million surpassing both its short and long-term liabilities, and it operates without debt. The company has demonstrated impressive earnings growth, with a 92% increase over the past year and net profit margins improving to 8.3%. Despite a less experienced board with an average tenure of 2.8 years, the management team is seasoned. Recent earnings report for the first half of 2025 shows revenue at CN¥432.76 million, reflecting strong operational performance in the sauna product market in China amidst ongoing governance amendments.</p>
<div class="lb-trans"><p>永益健康有限公司展现出强大的财务基础，短期资产为 CN¥9.989 亿，超过其短期和长期负债，并且没有债务。公司表现出令人印象深刻的收益增长，过去一年增长 92%，净利润率提高至 8.3%。尽管董事会经验较少，平均任期为 2.8 年，但管理团队经验丰富。2025 年上半年的最新收益报告显示，收入为 CN¥4.3276 亿，反映出在中国桑拿产品市场的强劲运营表现，尽管治理修订仍在进行中。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of Youngy Health.</li>
<li>Gain insights into Youngy Health's past trends and performance with our report on the company's historical track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解永益健康的完整分析健康报告。</li>
<li>通过我们的公司历史业绩报告获取永益健康的过去趋势和表现的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/2605bae5-5579-42d6-8c29-80393c734ae8/chart/financial-position-analysis"/></p>
<p>SZSE:300247 Financial Position Analysis as at Sep 2025</p>
<div class="lb-trans"><p>深交所：300247 财务状况分析截至 2025 年 9 月</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用优势</h2>
</div><ul>
<li>Navigate through the entire inventory of 976 Asian Penny Stocks here.</li>
<li>Contemplating Other Strategies? Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里浏览 976 只亚洲便士股票的完整清单。</li>
<li>考虑其他策略？探索 24 家在下一代技术革命中处于领先地位的量子计算公司，这些公司通过量子算法、超导量子比特和前沿研究塑造未来。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰写，内容具有一般性。<strong>我们基于历史数据和分析师预测提供评论，仅使用无偏见的方法，我们的文章不构成财务建议。</strong> 这并不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均没有持仓。</em></p>
</div>